

RealRate

PHARMACEUTICAL 2022











PHARMACEUTICAL 2022



RealRate

Immuneering Corp Rank 54 of 466

The relative strengths and weaknesses of Immuneering Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immuneering Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Immuneering Corp is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 265%, being 187% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	152,334
Cost of Goods Sold	1,153
Intangible Assets	7,141
Liabilities, Current	5,634
Liabilities, Non-Current	5,091
Other Assets	6,423
Other Compr. Net Income	-49
Other Expenses	-307
Other Liabilities	0
Other Net Income	43
Other Revenues	2,080
Property and Equipment	807
Research and Development	26,541
Selling, General and Administrative Expense	8,272

Output Variable	Value in 1000 USD
Assets	166,705
Liabilities	10,725
Expenses	35,659
Revenues	2,080
Stockholders Equity	155,980
Net Income	-33,536
Comprehensive Net Income	-33,560
Economic Capital Ratio	265%

